Leaders in Fertility
The thought of welcoming a new baby to a loving home is an exciting prospect for many parents. Strollers, birth announcements and baby showers take on new meaning as a sign of the future. But for people struggling to start a family, these cues serve as painful reminders of the one thing they don't yet have. This emotionally uncertain and frustrating journey is more common than many might think; in fact, 1 in 8 U.S. couples experiences difficulty conceiving.1
The good news: there is hope for a number of those couples impacted by infertility. EMD Serono has been a leader in the space, offering drugs, devices, technologies and services to help couples throughout fertility treatment.
Our Fertility Products
More than 20 years ago, we brought to market GONAL-f® (follitropin alfa for injection), one of the first recombinant human products used in the treatment of infertility. We proceeded to build a portfolio of complementary products and devices to use during a fertility treatment cycle, including Ovidrel® PreFilled Syringe (choriogonadotropin alfa injection) and Cetrotide® (cetrorelix acetate for injection).
Important Safety Information
These products should only be prescribed by physicians specializing in fertility or reproductive health. Risks include the following events which can be serious: allergic reactions; ovarian hyperstimulation syndrome (OHSS); lung problems, blood clots, and multiple births. For complete product details about a specific fertility drug, please refer to the Full Prescribing Information for full disclosure.
- Full Prescribing Information for GONAL-F® RFF REDI-JECT™ (follitropin alfa injection) (PDF)
- GONAL-f® (follitropin alfa for injection) Multi-Dose: Full Prescribing Information (PDF)
- GONAL-f® RFF (follitropin alfa for injection) 75 IU: Full prescribing information (PDF)
- Ovidrel® PreFilled Syringe (choriogonadotropin alfa injection): Full prescribing information (PDF)
- Cetrotide® (cetrorelix acetate for injection): Full prescribing information (PDF)
Caring for the whole patient
Visit our resources
Bridging to the Future of Fertility
That’s why we are exploring a scientific partnership model where we will partner with key fertility centers to conduct scientific studies and gather data to assess our technology-focused product portfolio - including Geri® and Gidget® - and determine its optimal value within the marketplace.
We see this as a launching pad for scientific engagement and a new way of exploring our ongoing commitment to the fertility community.
Over time, we hope these technologies will help to improve standardization and consistency and ultimately drive better outcomes for patients facing infertility.